NEURO360 partner work led by Randall J. Bateman, MD, is advancing global Alzheimer’s prevention trials through WashU’s DIAN-TU, which is testing whether anti-amyloid antibody therapies can stop the disease before symptoms begin. Early results indicate that amyloid clearance can slow cognitive decline by about 30% in symptomatic patients, and beginning treatment earlier in genetically at-risk individuals may delay dementia onset even further.

Read the full story on CBS News by clicking here.